Thermo Fisher Scientific stock hits 52-week high at 647.72 USD

Thermo Fisher Scientific's stock achieved a 52-week high of 647.72 USD, signifying a notable achievement for the $237.9 billion life sciences conglomerate. Throughout the preceding year, the stock exhibited a 36.56% gain, with a more intensified 36.7% surge in the past six months. This consistent rise highlights investors' growing faith in the company's market standing and robust performance.

However, InvestingPro's analysis suggests that the stock may be slightly overvalued compared to its Fair Value estimate, which could draw the attention of investors who follow the platform's Most Overvalued stocks list. This 52-week high underscores Thermo Fisher Scientific's dominant position in the industry and its capability to harness growth opportunities effectively.

Investors who seek a deeper understanding of the company's valuation and growth potential can explore the detailed Pro Research Report, which is accessible for TMO and over 1,400 other US equities on InvestingPro. Recently, Thermo Fisher Scientific disclosed its Q2 2026 earnings, surpassing Wall Street's expectations with adjusted earnings of $6.03 per share and revenue of $11.99 billion.

This outcome eclipsed the analysts' projections of $5.72 per share and $11.71 billion in sales. The company's achievement is largely attributed to heightened customer activity across diverse end markets, resulting in a 10% increase in revenue compared to the prior year. The growth was driven by both organic expansion (5%) and acquisitions (5%).

Moreover, Thermo Fisher Scientific increased its full-year 2026 revenue and adjusted earnings per share guidance due to its impressive first-half performance. In addition, UBS upgraded Thermo Fisher Scientific's stock rating from Neutral to Buy, setting a price target of $730 from the previous $540. UBS anticipates a return to 5% to 6% organic revenue growth by 2027, alongside operating margin enhancement and double-digit earnings per share growth.

This upgrade reflects a favorable outlook for the company, driven by improved demand in the pharmaceutical and biotech sectors, alongside favorable conditions in academic and government markets. The recent acquisitions have also significantly bolstered Thermo Fisher Scientific's overall performance. This report was AI-assisted and reviewed by an editor, ensuring accuracy and quality.